- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03067506
Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology
A Single Center Pilot Study to Evaluate Real Time Passive and Active High-Frequency Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The novel method being tested in this study for assessing mood and cognition in participants with MDD was wearable technology. This study looked at the correlation of mood and cognition outcomes on wearable technology with traditional objective neuropsychological cognitive function tests and self-reported mood outcomes.
The study enrolled approximately 30 patients. Participants were provided with a watch on which brief cognitive and mood tests were evaluated daily up to 6 weeks.
All participants prompted to complete cognitive and mood assessments on 3 occasions across the day. Two occasions (morning and afternoon) comprised assessment of cognition, and the final assessment in the evening constituted a review of the day focusing on self-reported depressed mood.
This single-center trial was conducted in United Kingdom. The overall time to participate in this study was 6 weeks. Participants took part up to 5 study visits (1 in-person on-site visit, 3 web-based and 1 at home visit) assessing performance on traditional objective neuropsychological cognitive function tests and self-reported measures of depression symptom severity and social function.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
London, Regno Unito
- Takeda Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Has MDD as the primary psychiatric diagnosis.
- Has been treated previously with at least 1 antidepressant (monotherapy).
- Has scores on Participant Health Questionnaire-9 items (PHQ-9) ≥5 and PHQ-9 ≤15 at Screening
Exclusion Criteria:
- Has a significant risk of suicide according to the investigator's clinical judgment or has made an actual suicide attempt in the previous 6 months prior to Screening.
- Has a history of only responding to either combination or augmentation therapy in the current episode and has had been treated for more than a year without any period of remission.
Has 1 or more of the following:
- Current or history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).
- Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine).
- Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Coorte
- Prospettive temporali: Prospettiva
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
Participants With Major Depressive Disorder (MDD)
Participants with MDD were provided with an Apple watch on which brief cognitive and mood tests were evaluated daily up to 6 weeks.
|
Nessun intervento
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Days on Which Daily N-back Sessions Were Completed
Lasso di tempo: Baseline up to Week 6
|
The cognitive assessment n-back test was completed on the wearable technology (Apple watch) on 3 occasions across the day in the morning, afternoon and evening.
|
Baseline up to Week 6
|
Percentage of Days on Which Daily Mood Assessment Tests Were Completed
Lasso di tempo: Baseline up to Week 6
|
The Daily Mood assessments were completed on the wearable technology (Apple watch) once per day in the afternoon or evening.
|
Baseline up to Week 6
|
Correlation Coefficient Between Measures of Cognition (N-back Scores) and Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) Tests: Spatial Working Memory Between Errors (SWMBE) and Spatial Working Memory Strategy (SWMS)
Lasso di tempo: Baseline up to Week 6
|
The n-back was used to assess cognition 3 times a day. Participants responded by touching the watch face when a symbol matched the one presented 2-back. Average daily n-back score (d-prime) was calculated. CANTAB tests consists of a battery of neuropsychological tests. Spatial Working Memory (SWM) assessed retention of spatial data, ability to manipulate remembered items and strategize. Participant was asked to find tokens in on-screen boxes and move them. SWMBE=cumulative number of times participant went back to box that a token was previously removed per each successful study. Lower score was better. SWMS=number of unique boxes participant searched in two 6 and 8 box trials. Total of 4 trial scores ranged from 4-28. Lower score indicated better performance. Pearson's correlation coefficient measured linear correlation between n-back scores from Apple Watch and CANTAB tests, provided as a value +1=positive correlation to -1=negative correlation. 0=no correlation. |
Baseline up to Week 6
|
Correlation Coefficient Between Measures of Cognition (N-back Scores) and Performance on the CANTAB Test: Rapid Visual Information Processing (RVP)
Lasso di tempo: Baseline up to Week 6
|
The n-back was used to assess cognition 3 times a day. Participants responded by touching the watch face when a symbol matched the one presented 2-back. Average daily n-back score (d-prime) was calculated. CANTAB tests consists of a battery of neuropsychological tests. RVP measures sustained attention. A white box appears in the center of the computer screen, inside which digits, from 2 to 9, appear in a pseudo-random order, at the rate of 100 digits per minute. Participants are requested to detect target sequences of digits. RVPA=measure of sensitivity to the target, regardless of response tendency (expected range is 0.00 to 1.00). Speed of Processing (RVPMDL)=The mean response latency during assessment sequence blocks where the participant responded correctly. Pearson's correlation coefficient measured linear correlation between n-back scores from Apple Watch and CANTAB tests, provided a value +1=positive correlation to -1=negative correlation. 0=no correlation. |
Baseline up to Week 6
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MDD-5003
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Disturbo depressivo maggiore
-
National Institute of Allergy and Infectious Diseases...CompletatoVariola Major (vaiolo)Stati Uniti
-
National Institute of Allergy and Infectious Diseases...Completato
-
China Medical University HospitalCompletato
-
bluebird bioCompletato
-
CorrectSequence Therapeutics Co., LtdReclutamento
-
Memorial Sloan Kettering Cancer CenterAttivo, non reclutanteDiagnosi confermata di ß-talassemia MajorStati Uniti
-
Tanta UniversitySconosciutoNigella sativa con beta talassemia majorEgitto
-
Tanta UniversitySconosciutoAL-Hijama nella Thalassmia MajorEgitto
-
Hamad Medical CorporationTerminatoOsteoporosi | Talassemia Majors (Beta-talassemia Major)Qatar
-
Affiliated hospital of guangxi medical university...Zhongshan Hospital Xiamen University; The Affiliated Nanjing Drum Tower Hospital... e altri collaboratoriSconosciuto
Prove cliniche su Nessun intervento
-
RadiancyCompletatoLombalgia cronica da lieve a moderataIsraele
-
University of PittsburghReclutamentoDistrofia muscolare di DuchenneStati Uniti
-
Sarah MorrowLawson Health Research InstituteCompletato
-
University of TulsaTerminatoSuicidio, tentatoStati Uniti
-
Lisbon Institute of Global Mental Health - LIGMHColumbia UniversityReclutamentoDisturbi psicotici | Schizofrenia | Disordine bipolare | Disturbo affettivo schizoidePortogallo
-
Indiana UniversityUniversity of South Florida; National Institute on Minority Health and Health... e altri collaboratoriCompletatoIntervento DECIDE modificato | Trattamento come consueto gruppo di curaStati Uniti
-
University of MichiganNational Institute on Drug Abuse (NIDA)ReclutamentoUso di cannabisStati Uniti
-
Icahn School of Medicine at Mount SinaiReclutamento
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)ReclutamentoProfilassi pre-esposizione all'HIVStati Uniti
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completato